Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2302024A
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular
01
Overview
GSK2302024A is a therapeutic peptide vaccine developed as a cancer immunotherapy targeting the Wilms' Tumor 1 (WT1) antigen. It is classified as a genetically engineered subunit vaccine and functions as an immunomodulator, specifically designed to stimulate an immune response against cells expressing the WT1 protein, which is overexpressed in various cancers. The drug was primarily investigated for use in breast cancer, particularly as neoadjuvant therapy in combination with standard treatments. Developed by GSK (GlaxoSmithKline), it reached phase II clinical trials before development was discontinued for breast cancer[1][3][9]. Side effects observed during trials included injection site reactions, flu-like symptoms, fatigue, gastrointestinal disturbances, and potential risks to organs that naturally express WT1 such as kidneys and heart[4].
- Other names
- recombinant WT1 antigen-specific cancer immunotherapeuticWT1 ASCIWT-1 ASCIWT 1 ASCIWT1-A10/AS15 ASCI
02
Targets
MHC I (MHC class I})CD8A (CD8 alpha/beta Coreceptor)WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on GSK2302024A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2302024A.